The carbacephems: A new beta-lactam antibiotic class
The carbacephems are a new class of β-lactam antibiotics that are similar in structure to the cephalosporins. Carbacephems differ from cephalosporins, however, in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. The result of thi...
Gespeichert in:
Veröffentlicht in: | The American journal of medicine 1992-06, Vol.92 (6), p.S2-S6 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | S6 |
---|---|
container_issue | 6 |
container_start_page | S2 |
container_title | The American journal of medicine |
container_volume | 92 |
creator | Cooper, Robin D.G. |
description | The carbacephems are a new class of β-lactam antibiotics that are similar in structure to the cephalosporins. Carbacephems differ from cephalosporins, however, in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. The result of this structural difference is the carbacephem class. Carbacephems have remarkable chemical stability that allows for structural manipulation in a manner that could not be done previously with the cephalosporin ring system. Potent broad-spectrum antibiotics result from the incorporation at the 3 position of substituents that include quaternary pyridinium or imidazole, sulfones, and heterocyclic thiazole structures. Because of the chemical stability of the carbacephems, these highly electronegative side chains can be added to the 3 or 3′ position of the tetrahydropyridine ring system. Increasing the electronegativity of these side chains can increase the microbiologic activity of the compounds. In addition, utilizing the side chains that have traditionally conferred good oral absorption on the cephalosporins offers the possibility of a new series of broad-spectrum oral antibiotics. Loracarbef is the first carbacephem to undergo clinical development, and other experimental carbacephems are being produced with the aim of developing potent oral antibiotics that can be used against pathogens that cause infections commonly found in the outpatient setting. |
doi_str_mv | 10.1016/0002-9343(92)90600-G |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73057264</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>000293439290600G</els_id><sourcerecordid>73057264</sourcerecordid><originalsourceid>FETCH-LOGICAL-c454t-482b391dea9aeec1ee093806c52993a533daf29dd0f6242edd4bd55b6c7ab9993</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMotVbfQGFwIboYzX0aF0IpWoWCm7oOmeSUpsylJjOKb29Ki4ILV4fD_50LH0LnBN8STOQdxpjminF2reiNwhLjfHaAhkQIkRdE0kM0_EGO0UmM69RiJeQADVJMCk6GiC9WkFkTSmNhs4I63meTrIHPrITO5JWxnakz03S-9G3nbWYrE-MpOlqaKsLZvo7Q29PjYvqcz19nL9PJPLdc8C7nY1oyRRwYZQAsAcCKjbG0girFjGDMmSVVzuGlpJyCc7x0QpTSFqZUCRmhq93eTWjfe4idrn20UFWmgbaPumBYFFTyBF7-AddtH5r0m6aMMoIlYwniO8iGNsYAS70JvjbhSxOst0b1Vpfe6tIq1a1RPUtjF_vdfVmD-x3aKUz5wy6HZOLDQ9DRemgsOB_Adtq1_v8D370cgvQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>232310633</pqid></control><display><type>article</type><title>The carbacephems: A new beta-lactam antibiotic class</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Cooper, Robin D.G.</creator><creatorcontrib>Cooper, Robin D.G.</creatorcontrib><description>The carbacephems are a new class of β-lactam antibiotics that are similar in structure to the cephalosporins. Carbacephems differ from cephalosporins, however, in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. The result of this structural difference is the carbacephem class. Carbacephems have remarkable chemical stability that allows for structural manipulation in a manner that could not be done previously with the cephalosporin ring system. Potent broad-spectrum antibiotics result from the incorporation at the 3 position of substituents that include quaternary pyridinium or imidazole, sulfones, and heterocyclic thiazole structures. Because of the chemical stability of the carbacephems, these highly electronegative side chains can be added to the 3 or 3′ position of the tetrahydropyridine ring system. Increasing the electronegativity of these side chains can increase the microbiologic activity of the compounds. In addition, utilizing the side chains that have traditionally conferred good oral absorption on the cephalosporins offers the possibility of a new series of broad-spectrum oral antibiotics. Loracarbef is the first carbacephem to undergo clinical development, and other experimental carbacephems are being produced with the aim of developing potent oral antibiotics that can be used against pathogens that cause infections commonly found in the outpatient setting.</description><identifier>ISSN: 0002-9343</identifier><identifier>EISSN: 1555-7162</identifier><identifier>DOI: 10.1016/0002-9343(92)90600-G</identifier><identifier>PMID: 1621741</identifier><identifier>CODEN: AJMEAZ</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Ambulatory Care ; Animals ; Anti-Bacterial Agents - chemistry ; Anti-Bacterial Agents - classification ; Antibiotics ; Biological Availability ; Cephalosporins - chemistry ; Cephalosporins - pharmacokinetics ; Cephalosporins - pharmacology ; Chemistry ; Clinical Trials as Topic ; Dogs ; Drug Evaluation, Preclinical ; Drug Stability ; Esters ; Haplorhini ; Humans ; Medical research ; Mice ; Microbial Sensitivity Tests</subject><ispartof>The American journal of medicine, 1992-06, Vol.92 (6), p.S2-S6</ispartof><rights>1992</rights><rights>Copyright Elsevier Sequoia S.A. Jun 22, 1992</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c454t-482b391dea9aeec1ee093806c52993a533daf29dd0f6242edd4bd55b6c7ab9993</citedby><cites>FETCH-LOGICAL-c454t-482b391dea9aeec1ee093806c52993a533daf29dd0f6242edd4bd55b6c7ab9993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0002-9343(92)90600-G$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1621741$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cooper, Robin D.G.</creatorcontrib><title>The carbacephems: A new beta-lactam antibiotic class</title><title>The American journal of medicine</title><addtitle>Am J Med</addtitle><description>The carbacephems are a new class of β-lactam antibiotics that are similar in structure to the cephalosporins. Carbacephems differ from cephalosporins, however, in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. The result of this structural difference is the carbacephem class. Carbacephems have remarkable chemical stability that allows for structural manipulation in a manner that could not be done previously with the cephalosporin ring system. Potent broad-spectrum antibiotics result from the incorporation at the 3 position of substituents that include quaternary pyridinium or imidazole, sulfones, and heterocyclic thiazole structures. Because of the chemical stability of the carbacephems, these highly electronegative side chains can be added to the 3 or 3′ position of the tetrahydropyridine ring system. Increasing the electronegativity of these side chains can increase the microbiologic activity of the compounds. In addition, utilizing the side chains that have traditionally conferred good oral absorption on the cephalosporins offers the possibility of a new series of broad-spectrum oral antibiotics. Loracarbef is the first carbacephem to undergo clinical development, and other experimental carbacephems are being produced with the aim of developing potent oral antibiotics that can be used against pathogens that cause infections commonly found in the outpatient setting.</description><subject>Ambulatory Care</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - chemistry</subject><subject>Anti-Bacterial Agents - classification</subject><subject>Antibiotics</subject><subject>Biological Availability</subject><subject>Cephalosporins - chemistry</subject><subject>Cephalosporins - pharmacokinetics</subject><subject>Cephalosporins - pharmacology</subject><subject>Chemistry</subject><subject>Clinical Trials as Topic</subject><subject>Dogs</subject><subject>Drug Evaluation, Preclinical</subject><subject>Drug Stability</subject><subject>Esters</subject><subject>Haplorhini</subject><subject>Humans</subject><subject>Medical research</subject><subject>Mice</subject><subject>Microbial Sensitivity Tests</subject><issn>0002-9343</issn><issn>1555-7162</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKAzEUhoMotVbfQGFwIboYzX0aF0IpWoWCm7oOmeSUpsylJjOKb29Ki4ILV4fD_50LH0LnBN8STOQdxpjminF2reiNwhLjfHaAhkQIkRdE0kM0_EGO0UmM69RiJeQADVJMCk6GiC9WkFkTSmNhs4I63meTrIHPrITO5JWxnakz03S-9G3nbWYrE-MpOlqaKsLZvo7Q29PjYvqcz19nL9PJPLdc8C7nY1oyRRwYZQAsAcCKjbG0girFjGDMmSVVzuGlpJyCc7x0QpTSFqZUCRmhq93eTWjfe4idrn20UFWmgbaPumBYFFTyBF7-AddtH5r0m6aMMoIlYwniO8iGNsYAS70JvjbhSxOst0b1Vpfe6tIq1a1RPUtjF_vdfVmD-x3aKUz5wy6HZOLDQ9DRemgsOB_Adtq1_v8D370cgvQ</recordid><startdate>19920622</startdate><enddate>19920622</enddate><creator>Cooper, Robin D.G.</creator><general>Elsevier Inc</general><general>Elsevier Sequoia S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>19920622</creationdate><title>The carbacephems: A new beta-lactam antibiotic class</title><author>Cooper, Robin D.G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c454t-482b391dea9aeec1ee093806c52993a533daf29dd0f6242edd4bd55b6c7ab9993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Ambulatory Care</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - chemistry</topic><topic>Anti-Bacterial Agents - classification</topic><topic>Antibiotics</topic><topic>Biological Availability</topic><topic>Cephalosporins - chemistry</topic><topic>Cephalosporins - pharmacokinetics</topic><topic>Cephalosporins - pharmacology</topic><topic>Chemistry</topic><topic>Clinical Trials as Topic</topic><topic>Dogs</topic><topic>Drug Evaluation, Preclinical</topic><topic>Drug Stability</topic><topic>Esters</topic><topic>Haplorhini</topic><topic>Humans</topic><topic>Medical research</topic><topic>Mice</topic><topic>Microbial Sensitivity Tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cooper, Robin D.G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cooper, Robin D.G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The carbacephems: A new beta-lactam antibiotic class</atitle><jtitle>The American journal of medicine</jtitle><addtitle>Am J Med</addtitle><date>1992-06-22</date><risdate>1992</risdate><volume>92</volume><issue>6</issue><spage>S2</spage><epage>S6</epage><pages>S2-S6</pages><issn>0002-9343</issn><eissn>1555-7162</eissn><coden>AJMEAZ</coden><abstract>The carbacephems are a new class of β-lactam antibiotics that are similar in structure to the cephalosporins. Carbacephems differ from cephalosporins, however, in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. The result of this structural difference is the carbacephem class. Carbacephems have remarkable chemical stability that allows for structural manipulation in a manner that could not be done previously with the cephalosporin ring system. Potent broad-spectrum antibiotics result from the incorporation at the 3 position of substituents that include quaternary pyridinium or imidazole, sulfones, and heterocyclic thiazole structures. Because of the chemical stability of the carbacephems, these highly electronegative side chains can be added to the 3 or 3′ position of the tetrahydropyridine ring system. Increasing the electronegativity of these side chains can increase the microbiologic activity of the compounds. In addition, utilizing the side chains that have traditionally conferred good oral absorption on the cephalosporins offers the possibility of a new series of broad-spectrum oral antibiotics. Loracarbef is the first carbacephem to undergo clinical development, and other experimental carbacephems are being produced with the aim of developing potent oral antibiotics that can be used against pathogens that cause infections commonly found in the outpatient setting.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>1621741</pmid><doi>10.1016/0002-9343(92)90600-G</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-9343 |
ispartof | The American journal of medicine, 1992-06, Vol.92 (6), p.S2-S6 |
issn | 0002-9343 1555-7162 |
language | eng |
recordid | cdi_proquest_miscellaneous_73057264 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Ambulatory Care Animals Anti-Bacterial Agents - chemistry Anti-Bacterial Agents - classification Antibiotics Biological Availability Cephalosporins - chemistry Cephalosporins - pharmacokinetics Cephalosporins - pharmacology Chemistry Clinical Trials as Topic Dogs Drug Evaluation, Preclinical Drug Stability Esters Haplorhini Humans Medical research Mice Microbial Sensitivity Tests |
title | The carbacephems: A new beta-lactam antibiotic class |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T14%3A40%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20carbacephems:%20A%20new%20beta-lactam%20antibiotic%20class&rft.jtitle=The%20American%20journal%20of%20medicine&rft.au=Cooper,%20Robin%20D.G.&rft.date=1992-06-22&rft.volume=92&rft.issue=6&rft.spage=S2&rft.epage=S6&rft.pages=S2-S6&rft.issn=0002-9343&rft.eissn=1555-7162&rft.coden=AJMEAZ&rft_id=info:doi/10.1016/0002-9343(92)90600-G&rft_dat=%3Cproquest_cross%3E73057264%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=232310633&rft_id=info:pmid/1621741&rft_els_id=000293439290600G&rfr_iscdi=true |